Table 1.
Characterization of the study population.
| SARS-CoV-2 infection | Non-pulmonary sepsis infection | pINF | |||||
|---|---|---|---|---|---|---|---|
| Cases | healthy controls | pSARS | cases | healthy controls | pSEP | ||
| subjects, n (%) | 16 (25.0) | 32 (75.0) | – | 12 (25.0) | 24 (75.0) | – | – |
| female sex, n (%)a |
5 (31.25) | 16 (50.0) | 0.35 | 7 (58.33) | 16 (75.0) | 0.90 | 0.30 |
| age, yearsb | 54.44 ± 19.93 | 55.5 (34.75; 61.0) | 0.3 | 68.17 ± 12.44 | 58.08 ± 5.98 | 0.02 | 0.03 |
| CRP, ng/mlb | 77.02 ± 62.96 | 1.0 (0.9; 1.2) | 2.25 x 10-3 | 224.2 (124.7; 279.2) | 1.0 (0.9; 1.13) | 7.61 x 10-5 | 3.04 x 10-3 |
| IL-6, pg/mlb | 90.21 ± 149.92 | 2.7 (2.15; 4.6) | 0.05 | – | 3.55 (2.15; 4.9) | – | – |
| CC16, ng/mlb | 96.22 ± 129.01 | 14.05 ± 7.48 | 0.022 | 35.37 ± 28.10 | 15.25 ± 7.51 | 0.032 | 0.09 |
Data was tested for normal distribution using Shapiro-wilk test. Normally distributed data are presented as mean ± standard deviation, non-normally distributed data as median (25th, 75th percentile). Categorical variables are presented as number of subjects (percentages). a Statistical significance was tested using Chi2-test. b Statistical significance was tested using t-tests. pSARS, comparison of SARS-CoV-2 cases and healthy controls; pSEP, comparison of sepsis cases and healthy controls; pINF, comparison of SARS-CoV-2 and sepsis cases. CRP, C-reactive protein; IL-6, interleukin 6; CC16, clara-cell 16 kDa protein.